Telcon Inc - Asset Resilience Ratio
Telcon Inc (200230) has an Asset Resilience Ratio of 15.21% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 200230 working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2025)
This chart shows how Telcon Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Telcon Inc.
Liquid Assets Composition Over Time
This chart breaks down Telcon Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore 200230 long-term investments to assets to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩22.88 Billion | 15.21% |
| Total Liquid Assets | ₩22.88 Billion | 15.21% |
Asset Resilience Insights
- Good Liquidity Position: Telcon Inc maintains a healthy 15.21% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Telcon Inc Industry Peers by Asset Resilience Ratio
Compare Telcon Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Kamada
TA:KMDA |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.48% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 4.31% |
|
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723 |
Drug Manufacturers - Specialty & Generic | 1.01% |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL |
Drug Manufacturers - Specialty & Generic | 5.90% |
Annual Asset Resilience Ratio for Telcon Inc (2013–2025)
The table below shows the annual Asset Resilience Ratio data for Telcon Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 3.83% | ₩6.00 Billion ≈ $4.07 Million |
₩156.67 Billion ≈ $106.17 Million |
-0.55pp |
| 2024-12-31 | 4.38% | ₩6.73 Billion ≈ $4.56 Million |
₩153.59 Billion ≈ $104.08 Million |
-3.10pp |
| 2023-12-31 | 7.49% | ₩10.51 Billion ≈ $7.12 Million |
₩140.41 Billion ≈ $95.16 Million |
-2.54pp |
| 2022-12-31 | 10.03% | ₩11.96 Billion ≈ $8.10 Million |
₩119.25 Billion ≈ $80.82 Million |
-3.77pp |
| 2021-12-31 | 13.80% | ₩23.19 Billion ≈ $15.72 Million |
₩168.03 Billion ≈ $113.87 Million |
+0.44pp |
| 2020-12-31 | 13.36% | ₩24.73 Billion ≈ $16.76 Million |
₩185.05 Billion ≈ $125.41 Million |
+1.30pp |
| 2019-12-31 | 12.07% | ₩15.88 Billion ≈ $10.76 Million |
₩131.65 Billion ≈ $89.22 Million |
+8.01pp |
| 2018-12-31 | 4.05% | ₩7.36 Billion ≈ $4.99 Million |
₩181.79 Billion ≈ $123.20 Million |
-10.25pp |
| 2017-12-31 | 14.30% | ₩29.98 Billion ≈ $20.32 Million |
₩209.64 Billion ≈ $142.07 Million |
+5.58pp |
| 2016-12-31 | 8.72% | ₩10.86 Billion ≈ $7.36 Million |
₩124.51 Billion ≈ $84.38 Million |
+8.62pp |
| 2015-12-31 | 0.10% | ₩50.00 Million ≈ $33.88K |
₩48.15 Billion ≈ $32.63 Million |
-12.87pp |
| 2014-12-31 | 12.97% | ₩6.20 Billion ≈ $4.20 Million |
₩47.76 Billion ≈ $32.37 Million |
+6.27pp |
| 2013-12-31 | 6.71% | ₩2.16 Billion ≈ $1.46 Million |
₩32.20 Billion ≈ $21.82 Million |
-- |
About Telcon Inc
TELCON RF PHARMACEUTICAL. Inc. primarily engages in the development, production, and sale of RF coaxial connectors worldwide. It also provides coaxial couplers, distributors, and arresters, as well as cable assemblies; and pharmaceuticals. The company was formerly known as Telcon Co., Ltd. TELCON RF PHARMACEUTICAL. Inc. was founded in 1999 and is headquartered in Yongin-si, South Korea.